No Evidence COVID-19 Vaccines Will Block Spread of Coronavirus
On Nov. 9, 2020, Pfizer, Inc. announced that the experimental messenger RNA (mRNA) BNT162b2 vaccine for COVID-19 it developed in partnership with Germany’s BioNTech SE had an efficacy rate of 90 percent, based on the results of human clinical trials on the vaccine.1 2 3 This news was followed up a week later with an […]
Pfizer CEO Sold $5.6 Million Stock in Pre-Planned Sale on Day of Vaccine News Release
We are learning more about a stock sale by Pfizer CEO Albert Bourla on Monday, the same day the company announced its early vaccine trial results. We’ve seen certain circumstances like this before. That’s right… so remember, of course, Pfizer reported that 90 percent efficacy number on its vaccine trial on Monday. Its stock went […]
Pfizer CEO Sells Stock Same Day Positive Results of COVID-19 Vaccine Announced
Story Highlights On Nov. 9, 2020, Pfizer released preliminary Phase 3 clinical trial data indicating that its experimental mRNA COVID-19 vaccine is 90 percent effective, triggering a big surge in stock price. Pfizer CEO Albert Bourla immediately sold 60 percent of his company stock, realizing a gain of $5.6 million in what the company called […]
Pharma’s Public Pledge On COVID-19 Vaccines
On Sept. 8, 2020, nine pharmaceutical companies working on COVID-19 vaccines signed a pledge saying they would not submit their experimental vaccines to the U.S. Food and Drug Administration (FDA) unless they were shown to be both safe and efficacious in the Phase 3 human clinical trials.1 2 3 4 5 The pledge, signed by […]
Pfizer and BioNTech Begin Human Clinical Trials of COVID-19 Vaccine in U.S.
Pfizer, Inc. of New York and BioNTech SE of Mainz, Germany have announced that human clinical trials for an experimental COVID-19 vaccine they have co-developed, known as BNT162, have begun in the United States.1 As part of a global clinical development program, the first human subjects in the U.S. Phase I and Phase clinical II […]